Grünenthal is a global leader in pain management. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

A mix of strong entrepreneurial spirit, close collaboration, and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Partnering

In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

Explore our media section and access a range of materials relating to our company.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2019 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

A World Free of Pain

Out now: Grünenthal Annual Report 2024/2025

Grünenthal is a global leader in pain management.

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.

Katrin Fleischer, Global Regulatory Strategy

Sabine Hess, Technician Cellular & Molecular Biology

Andrew Lockhart, Head Translational and Disease Understanding Unit

Grünenthal Stories

View All

Matt Crabb, Head Internal Communication talking to the Grünenthal Investor Relations team (Andrew Duncan & Anna Carduck) at a coffee point at the Grünenthal headquarters

Building trust with investors

Trust is the most important currency for investors. But how do people at Grünenthal earn and build that trust? Two representatives from our Investor Relations team share insights into their daily work of creating long-term, successful relationships with the financial community.

05 May 2025

E-G-G: 20 years of futuristic ideas

2024 is the twentieth anniversary of the EFIC-Grünenthal-Grant (E-G-G) for pain research. Previous winner Jonas Zaman describes how this unique funding programme impacted his life – and enabled further successes in his career as a pain scientist.

25 March 2025

ESG Top Rated

Grünenthal has again been placed among the industry’s top performers in its latest Sustainalytics ESG rating. We have been certified a strong management of environmental, social and governance issues and rated as “low risk”.

19 March 2025

E-G-G: Opening up new pain research

The EFIC-Grünenthal-Grant (E-G-G) has now funded pain research for 20 years. Joukje Oosterman won this prestigious grant in 2017 – and it enabled her to investigate fresh areas of research that are still helping to advance her career in pain science.

18 March 2025

E-G-G 2025: Three winning projects!

Chronic pain affects 20 percent of people worldwide. The EFIC-Grünenthal-Grant (E-G-G) aims to improve quality of life for those patients by supporting innovative pain research – and is now announcing its three winning projects for 2025!

12 March 2025

Joaquín López Ruiz, Sales Representative

Training, teams and treatments

Passion, team spirit and training are essential for wellbeing at work. That is the view expressed in this interview with Joaquín López Ruiz, who compares his 25-year commitment to Grünenthal with the deep loyalty football fans feel for their club.

12 February 2025

Phase III trial AV001 with QUTENZA®: Recruitment completed

Qutenza^® Phase III trial AV001: Recruitment completed

Grünentha's U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and tolerability of QUTENZA^® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and if successful could support an extension of the U.S. label.

Read the press release on the AV001 trial recruitment completion

NOP First-In-Human-Trial Announcement Grünenthal

First participants enrolled in Phase I NOP trial

Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025.

Get more insides in our press release

Grünenthal Report 2024/2025

Grünenthal has a clear, bold vision: a World Free of Pain. In 2024, we took big steps forward in developing innovative medicines for patients living with pain worldwide. The latest Grünenthal Report provides information about our key objectives and activities, as well as our recent business development highlights and financial performance.

The full Grünenthal Report is available here.

Responsibility Report 2023

Grünenthal’s strategy and culture are closely tied to its deep commitment to conducting business responsibly. We aim to have a net-positive impact on patients, employees, partners, and wider society. Each year, we publish our progress in a detailed and externally audited report – in line with the Global Reporting Initiative (GRI) standards.

Check out our latest Responsibility Report.